The pecking order of the obesity drug market is shifting. Eli Lilly , the $815 billion maker of blockbuster weight-loss drugs ...

Ozempic, originally for type 2 diabetes, has surged in popularity in North America as a weight-loss solution, sparking a ...

In patients with T2D who had been hospitalized for poorly controlled blood glucose, SGLT2 inhibitors nearly doubled the risk ...

The California Legislative Analyst’s Office reports the state’s drug spending has doubled since 2018, with a quarter of the ...

Gavin Newsom’s administration has reported that half of the doubling in Medi-Cal costs over the past six years has been from ...

A new study from Rutgers University links higher body dissatisfaction, BMI, and maladaptive weight loss behaviors with ...

Doctors have explained the potential pros and cons of these so-called 'skinny jabs', with everything from nausea to abdominal ...

Researchers link GLP1 agonists to depression risk in some users and call for personalized prescribing based on genetic ...

Two popular glucose-lowering drugs may protect against Alzheimer's disease and related dementias in patients with type 2 ...

The U.S. Food and Drug Administration on Monday warned consumers and pharmacies that fake versions of Ozempic, a drug to ...

The frequency of high blood glucose among patients receiving PI3K/Akt inhibitors to treat breast cancer has some oncologists ...

ProFuse's novel technology addresses the growing need to preserve muscle in the face of aging and the popularity of ...